Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck

NCT00210470 is registered in ClinicalTrials.gov with Brooklyn ImmunoTherapeutics, LLC as lead sponsor.

NCT NCT00210470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00210470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck
Lead sponsor
Brooklyn ImmunoTherapeutics, LLC
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
March 31, 2012
Enrollment
27 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck